Challenges and Opportunities in the Drug Eluting Balloon Industry
The Emergence of Sirolimus-Coated Balloons
While paclitaxel has long been the dominant drug in the drug eluting balloons market, the emergence of sirolimus-coated balloons is a key trend to watch. Sirolimus, an anti-proliferative drug that has been a cornerstone of drug-eluting stents, is now being used on balloons to provide a different set of clinical benefits. The growth of this segment is a key factor in the Drug Eluting Balloons Market report.
Sirolimus has a different mechanism of action and a different pharmacokinetic profile than paclitaxel. It is a highly effective anti-proliferative agent, but it is also less lipophilic, which has required new coating technologies to ensure its effective transfer to the vessel wall. The clinical evidence for sirolimus-coated balloons is still building, but early results are promising, particularly for coronary applications. The safety concerns that have been raised about paclitaxel have also created an opportunity for sirolimus-coated balloons to gain market share. As the clinical data continues to accumulate and as new products gain regulatory approval, the sirolimus-coated balloon segment is expected to grow at a faster rate than the overall market.